Long-term outcome of persons with diabetic and non-diabetic neuro-osteoarthropathy after foot correction using external fixation.


Journal

Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858

Informations de publication

Date de publication:
04 2021
Historique:
revised: 28 07 2020
received: 06 06 2020
accepted: 10 09 2020
pubmed: 20 9 2020
medline: 1 2 2022
entrez: 19 9 2020
Statut: ppublish

Résumé

Diabetic neuro-osteoarthropathy (Charcot foot) is a serious form of diabetic foot syndrome, often leading to severe deformity of the foot and subsequently to ulcers and osteomyelitis. The aim of this retrospective study was to determine the success rate and long-term outcomes for a Charcot foot operation using external fixation in 115 individuals who underwent surgery between July 2008 and December 2012. Some 115 consecutive persons, 78 (68%) men and 37 (32%) women, were enrolled in this study. The eligibility criterion for this retrospective study was reconstructive foot surgery using a Hoffmann II external fixator in diabetic and non-diabetic neuro-osteoarthropathy. The main examination parameters in the follow-up were walking ability, amputation and mortality. Average follow-up was 5.7 (± 3.2) years. Ninety-seven per cent of people were able to walk after the operation with bespoke shoes or an orthosis. At follow-up, 77% were able to walk and 51% were fully mobile even outside the home. Subsequent amputations were performed in 29 individuals (26%), with 17 (15%) minor and 12 (11%) major amputations. Forty-seven individuals died before follow-up, the majority (53%) from cardiovascular events. Average survival time post surgery was 4.5 (± 2.9) years. Reconstruction surgery using external fixation is a very useful method for maintaining walking ability in the case of conservatively non-treatable diabetic and non-diabetic neuro-osteoarthropathy. Individuals with severe Charcot foot disease had a low rate of major amputations. Osteomyelitis was the main reason for major amputations.

Identifiants

pubmed: 32949070
doi: 10.1111/dme.14404
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14404

Informations de copyright

© 2020 Diabetes UK.

Références

Petrova NL, Edmonds ME. Acute Charcot neuro-osteoarthropathy. Diabetes Metab Res Rev. 2016;32(Suppl 1):281-286.
Yousaf S, Dawe EJC, Saleh A, et al. The acute Charcot foot in diabetics: diagnosis and management. EFORT Open Rev. 2018;3:568-573.
Koller A, Springfeld R, Engels G, et al. German-Austrian consensus on operative treatment of Charcot neuroarthropathy: a perspective by the Charcot task force of the German Association for Foot Surgery. Diabet. Foot Ankle. 2011;2.
Simon SR, Tejwani SG, Wilson DL, et al. Arthrodesis as an early alternative to nonoperative management of Charcot arthropathy of the diabetic foot. J Bone Joint Surg Am. 2000;82-A:939-950.
Ersin M, Demirel M, Chodza M, et al. Mid-term results of hindfoot arthrodesis with a retrograde intra-medullary nail in 24 patients with diabetic Charcot neuroarthropathy. Acta Orthop. 2020;91:336-340.
Wirth SH, Viehofer AF, Tondelli T, et al. Mid-term walking ability after Charcot foot reconstruction using the Ilizarov ring fixator. Arch Orthop Trauma Surg. 2020; https://doi.org/10.1007/s00402-020-03407-5. [Epub ahead of print].
Koller A, Meissner SA, Podella M, et al. Orthotic management of Charcot feet after external fixation surgery. Clin Podiatr Med Surg. 2007;24:583-599.
Sanders L, Frykberg R. Charcot neuroarthropathy of the foot. In: Bowker JH and Pfeifer MA (eds) Levin and O’Neal’s The Diabetic Foot, 6th edn. St Louis, MO: Mosby, 2001:439-466.
Illgner U, Budny T, Frohne I, et al. Clinical benefit and improvement of activity level after reconstruction surgery of Charcot feet using external fixation: 24-months results of 292 feet. BMC Musculoskelet Disord. 2014;15:392.
Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care. 2000;23:796-800.
Gazis A, Pound N, Macfarlane R, et al. Mortality in patients with diabetic neuropathic osteoarthropathy (Charcot foot). Diabet Med. 2004;21:1243-1246.
van Baal J, Hubbard R, Game F, et al. Mortality associated with acute Charcot foot and neuropathic foot ulceration. Diabetes Care. 2010;33:1086-1089.
Elmarsafi T, Anghel EL, Sinkin J, et al. Risk factors associated with major lower extremity amputation after osseous diabetic Charcot reconstruction. J Foot Ankle Surg. 2019;58:295-300.
Ramanujam CL, Han D, Zgonis T. Lower extremity amputation and mortality rates in the reconstructed diabetic Charcot foot and ankle with external fixation: data analysis of 116 patients. Foot Ankle Spec. 2016;9:113-126.
Sohn MW, Stuck RM, Pinzur M, et al. Lower-extremity amputation risk after Charcot arthropathy and diabetic foot ulcer. Diabetes Care. 2010;33:98-100.
Wukich DK, Sadoskas D, Vaudreuil NJ, et al. Comparison of diabetic Charcot patients with and without foot wounds. Foot Ankle Int. 2017;38:140-148.
Richman J, Cota A, Weinfeld S. Intramedullary nailing and external ring fixation for tibiotalocalcaneal arthrodesis in Charcot arthropathy. Foot Ankle Int. 2017;38:149-152.
Yammine K, Assi C. Intramedullary nail versus external fixator for ankle arthrodesis in Charcot neuroarthropathy: a meta-analysis of comparative studies. J Orthop Surg (Hong Kong). 2019;27:2309499019836012.
Pinzur MS, Gil J, Belmares J. Treatment of osteomyelitis in Charcot foot with single-stage resection of infection, correction of deformity, and maintenance with ring fixation. Foot Ankle Int. 2012;33:1069-1074.
Dalla Paola L, Brocco E, Ceccacci T, et al. Limb salvage in Charcot foot and ankle osteomyelitis: combined use single stage/double stage of arthrodesis and external fixation. Foot Ankle Int. 2009;30:1065-1070.

Auteurs

A M S Spraul (AMS)

Department for Internal Medicine III, Mathias-Spital Rheine, Rheine, Germany.

A M Schönbach (AM)

Department for Internal Medicine III, Mathias-Spital Rheine, Rheine, Germany.

N Müller (N)

Department for Internal Medicine III, Jena University Hospital, Jena, Germany.

U A Müller (UA)

Practice for Endocrinology and Diabetology, Dr. Kielstein Ambulante Medizinische Betreuung GmbH, Jena, Germany.

A Koller (A)

Department of Foot Surgery, Klinik Dr Guth, Hamburg, Germany.

M Spraul (M)

Department for Internal Medicine III, Mathias-Spital Rheine, Rheine, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH